An expert in infectious diseases reviews best practices for improving personalized medicine when treating complicated urinary tract infections and highlights the importance of antimicrobial stewardship.
Kim Leuthner, PharmD, FIDSA
Advertisement
Articles by Kim Leuthner, PharmD, FIDSA
Kim Leuthner, PharmD, FIDSA, comments on the effect of COVID-19 on the epidemiology of complicated UTIs, the use of antibiotics, and antimicrobial resistance.
An infectious disease clinical specialist shares treatment considerations for patients with complicated urinary tract infections, including for patients with comorbidities and older patients, and reviews antimicrobial therapies for multidrug-resistant UTIs.
Kim Leuthner, PharmD, FIDSA, provides insight on distinguishing between complicated and uncomplicated UTIs, and patients who are at high risk for developing complicated UTIs.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Contagion Live
1
Clinical Takeaways From ViiV’s PASO DOBLE and CLARITY Studies
2
Phage and Antibiotic Combination Therapy for Biofilm-Associated Bacterial Infections
3
Rapid HCV Test Provides Opportunity for Single Visit Diagnosis and Treatment Encounters
4
Balancing Early Discharge and Follow-Up Challenges in Skin Infection Care
5
